7.25
price up icon5.69%   0.39
after-market Dopo l'orario di chiusura: 7.24 -0.010 -0.14%
loading
Precedente Chiudi:
$6.86
Aprire:
$6.97
Volume 24 ore:
28,314
Relative Volume:
0.14
Capitalizzazione di mercato:
$42.48M
Reddito:
$100.44M
Utile/perdita netta:
$-133.16M
Rapporto P/E:
-0.2814
EPS:
-25.76
Flusso di cassa netto:
$-94.85M
1 W Prestazione:
+5.07%
1M Prestazione:
-15.60%
6M Prestazione:
-25.41%
1 anno Prestazione:
-53.97%
Intervallo 1D:
Value
$6.6701
$7.25
Intervallo di 1 settimana:
Value
$5.94
$7.25
Portata 52W:
Value
$5.40
$20.81

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Name
Nome
Atara Biotherapeutics Inc
Name
Telefono
805-623-4211
Name
Indirizzo
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Name
Dipendente
153
Name
Cinguettio
@Atarabio
Name
Prossima data di guadagno
2024-11-18
Name
Ultimi documenti SEC
Name
ATRA's Discussions on Twitter

Confronta ATRA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ATRA
Atara Biotherapeutics Inc
7.25 42.48M 100.44M -133.16M -94.85M -25.76
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
504.77 129.62B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
666.87 72.91B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
604.96 36.76B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.76 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
259.19 27.86B 3.32B -860.46M -1.04B -8.32

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-11-09 Downgrade Evercore ISI Outperform → In-line
2023-11-09 Downgrade H.C. Wainwright Buy → Neutral
2023-11-09 Downgrade Mizuho Buy → Neutral
2022-07-20 Downgrade Citigroup Neutral → Sell
2022-07-13 Downgrade JP Morgan Overweight → Neutral
2022-07-13 Downgrade Stifel Buy → Hold
2022-05-10 Downgrade Citigroup Buy → Neutral
2021-05-13 Aggiornamento JP Morgan Neutral → Overweight
2020-12-09 Downgrade Citigroup Buy → Neutral
2020-12-08 Reiterato H.C. Wainwright Buy
2020-11-10 Reiterato H.C. Wainwright Buy
2020-06-30 Iniziato Evercore ISI Outperform
2020-06-15 Iniziato H.C. Wainwright Buy
2020-04-23 Aggiornamento Citigroup Neutral → Buy
2019-11-08 Downgrade JP Morgan Overweight → Neutral
2019-09-27 Downgrade Goldman Neutral → Sell
2019-09-16 Downgrade Jefferies Buy → Hold
2019-06-04 Aggiornamento Citigroup Sell → Neutral
2019-05-30 Iniziato ROTH Capital Buy
2019-05-23 Iniziato Stifel Buy
2019-01-23 Iniziato Mizuho Buy
2018-04-10 Iniziato JP Morgan Overweight
2018-03-16 Iniziato Guggenheim Neutral
2018-03-05 Reiterato Jefferies Buy
2018-02-28 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2018-02-15 Downgrade Citigroup Neutral → Sell
2018-01-03 Aggiornamento Citigroup Sell → Neutral
2017-10-06 Ripresa Goldman Neutral
Mostra tutto

Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie

pulisher
Mar 13, 2025

Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Mar 13, 2025
pulisher
Mar 12, 2025

Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Atara Biotherapeutics: Q4 Earnings Snapshot - The Bakersfield Californian

Mar 10, 2025
pulisher
Mar 09, 2025

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 09, 2025
pulisher
Mar 09, 2025

Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes - TipRanks

Mar 09, 2025
pulisher
Mar 07, 2025

Atara Biotherapeutics Reports 2024 Financial Results - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - BioSpace

Mar 07, 2025
pulisher
Mar 07, 2025

Atara Biotherapeutics Inc. (ATRA) reports earnings - Quartz

Mar 07, 2025
pulisher
Mar 07, 2025

Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace

Mar 07, 2025
pulisher
Mar 07, 2025

Atara Biotherapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop - Simply Wall St

Mar 07, 2025
pulisher
Mar 06, 2025

Nguyen AnhCo, CEO of Atara Biotherapeutics, sells $23,307 in stock By Investing.com - Investing.com Australia

Mar 06, 2025
pulisher
Mar 06, 2025

Atara biotherapeutics EVP and CFO Eric Hyllengren sells $8,473 in stock By Investing.com - Investing.com South Africa

Mar 06, 2025
pulisher
Mar 06, 2025

Atara biotherapeutics EVP and CFO Eric Hyllengren sells $8,473 in stock - Investing.com Australia

Mar 06, 2025
pulisher
Mar 05, 2025

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is i - GuruFocus.com

Mar 05, 2025
pulisher
Mar 05, 2025

Atara biotherapeutics EVP sells $7,409 in common stock - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Nguyen AnhCo, CEO of Atara Biotherapeutics, sells $23,307 in stock - Investing.com India

Mar 05, 2025
pulisher
Mar 04, 2025

Trading (ATRA) With Integrated Risk Controls - Stock Traders Daily

Mar 04, 2025
pulisher
Mar 03, 2025

Atara Biotherapeutics Inc To Cut 50% Of Workforce -March 03, 2025 at 05:26 pm EST - Marketscreener.com

Mar 03, 2025
pulisher
Feb 27, 2025

Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet - MSN

Feb 27, 2025
pulisher
Feb 26, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Feb 26, 2025
pulisher
Feb 21, 2025

(ATRA) Investment Analysis - Stock Traders Daily

Feb 21, 2025
pulisher
Feb 14, 2025

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - Finansavisen

Feb 14, 2025
pulisher
Feb 12, 2025

Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online

Feb 12, 2025
pulisher
Feb 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - Longview News-Journal

Feb 11, 2025
pulisher
Feb 11, 2025

How the (ATRA) price action is used to our Advantage - Stock Traders Daily

Feb 11, 2025
pulisher
Feb 11, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation - Markets Insider

Feb 11, 2025
pulisher
Feb 10, 2025

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Feb 10, 2025
pulisher
Feb 10, 2025

2025-02-10 | Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing

Feb 10, 2025
pulisher
Feb 09, 2025

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 - BioSpace

Feb 09, 2025
pulisher
Feb 09, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - Markets Insider

Feb 09, 2025
pulisher
Feb 09, 2025

2025-02-09 | Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing

Feb 09, 2025
pulisher
Feb 08, 2025

Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN

Feb 08, 2025
pulisher
Feb 08, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Brokerages - Armenian Reporter

Feb 08, 2025
pulisher
Feb 07, 2025

Atara Biotherapeutics (NASDAQ:ATRA) Stock Quotes, Forecast and News Summary - Benzinga

Feb 07, 2025
pulisher
Feb 07, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - Markets Insider

Feb 07, 2025
pulisher
Feb 06, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - Markets Insider

Feb 06, 2025
pulisher
Feb 05, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation - Markets Insider

Feb 05, 2025
pulisher
Feb 04, 2025

Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Price Target at $17.75 - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - Markets Insider

Feb 04, 2025
pulisher
Feb 04, 2025

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider

Feb 04, 2025
pulisher
Feb 03, 2025

Wolf Haldenstein Adler Freeman & Herz LLP announces that it - GlobeNewswire

Feb 03, 2025

Atara Biotherapeutics Inc Azioni (ATRA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$307.24
price up icon 0.61%
$76.55
price up icon 1.97%
$32.77
price up icon 0.28%
$20.79
price up icon 8.34%
$99.47
price up icon 2.06%
biotechnology ONC
$259.19
price up icon 1.81%
Capitalizzazione:     |  Volume (24 ore):